Please assess the completion status of the following clinical trial:

Trial Title: Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTX

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adults with moderate to severe RA (Rheumatoid Arthritis) who have not been treated with methotrexate.~* Diagnosis of RA based on the American College of Rheumatology 1987 revised criteria.~* Active disease as defined by both \>=6 tender or painful joints on motion and \>= 6 joints swollen; and either an erythrocyte sedimentation rate (ESR) \> 28 mm or a C-reactive protein (CRP) concentration \> 7 mg/dL~Exclusion Criteria:~* Blood dyscrasias including confirmed: Hemoglobin \<9 g/dL or Hematocrit \<30%; White blood cell count \<3.0 x 109/L; Absolute neutrophil count \<1.2 x 109/L; Platelet count \<100 x 109/L~* History of any other rheumatic autoimmune disease other than Sjogren's syndrome~* No malignancy or history of malignancy~* History of infection requiring hospitalization, parenteral antimicrobial therapy, or as otherwise judged clinically significant by the investigator, within the 6 months prior to the first dose of study drug~* No chronic liver disease, recent or active hepatitis or other contraindication to methotrexate therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- 5 mg BID CP-690,550 (Type: EXPERIMENTAL): None
- 10 mg BID CP-690,550 (Type: EXPERIMENTAL): None
- methotrexate (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).